An interventional study of Early PPD Screening in Postpartum Depression (PPD), sponsored by Massachusetts General Hospital. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.
Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 25th largest by planned enrollment of the 198 interventional ones that give a count, is one of 14 that started in 2026, is one of 152 with no phase, reaches primary completion later than 30 of the 48 other live ones, and was the 209th registered.
570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.
Browse Depression, Postpartum studies →38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:
University of South Carolina · Sites in United States
Ages 18+ · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
University of Florida · Sites in United States
Ages 15–49 · Women only
Lipocine Inc. · Sites in United States
Ages 15–45 · Women only
Northwestern University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Depression, Postpartum studies recruiting now, 54 (61%) set no upper age limit and 31 (35%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 14 · Phase 4 7
First in 1996; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 428 is above the median of 103 across 455 interventional studies indexed under Depression, Postpartum.
Median enrollment 86 across the 198 interventional studies, 175 across the 22 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 220 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 6 studies filed under Depression, Postpartum — fewer than ten, so there is no comparison to draw.
22 of the studies in Depression, Postpartum with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT07822321Phase 3Lipocine Inc.Brexanolone Lifting Outcomes Of Moms | 2027-08 |
| NCT05345834Children's National Research InstituteThe DC Mother-Infant Behavioral Wellness Program | 2026-11-30 |
| NCT06831968University of VirginiaClinical Validation of a Predictive Test for Postpartum Depression | 2026-11-30 |
| NCT06175104Children's Hospital Medical Center, CincinnatiHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 220 studies in Depression, Postpartum with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
After having a baby, some women develop a condition called postpartum depression, or PPD, which can cause sadness, anxiety, and difficulty bonding with their newborn. Right now, most women aren't screened for PPD until about 6 to 8 weeks after giving birth, but this study wants to find out if checking earlier could help identify signs sooner. To test this, researchers will work with 428 women who deliver at an MGH hospital clinic and have no history of depression. Each woman will be randomly placed into one of two groups: one group will fill out a short depression questionnaire online at 2 to 3 weeks after delivery, while the other group will follow the usual process and complete the same questionnaire at their regular 6-week visit. The results will go to each woman's doctor, who will decide if any follow-up care is needed, just like they normally would. The study will follow each participant for 6 months after delivery to see whether earlier screening makes a difference.
This is a pragmatic clinical trial comparing early EPDS screening (2 weeks postpartum) with standard care (6 weeks postpartum) in 428 patients without a history of depression and delivering and receiving obstetric care at an MGH-affiliated clinic. Patients will be stratified as high-risk or low-risk for PPD using a validated prediction model and then randomized (1:1) to one of two arms: early screening (intervention group) or routine care (control group). Patients and clinical team members will be blinded to risk assignment. The early EPDS screening group will be sent an electronic EPDS (PROMS) at 2-3 weeks postpartum by the MGH Obstetric Clinic Staff; results will be directed to the patient's primary obstetric provider, mirroring the clinical process for the routine 6-week postpartum EPDS screen. The routine care group will continue to receive standard postpartum care, which includes a visit around 6 to 8 weeks postpartum and administration of the EPDS survey. Clinic staff will review and manage screening results according to local clinic protocols (e.g., arranging virtual or in-person visits, social work referrals, etc.); this includes managing reports of self-harm, which is a component of the scale. The research team will not be responsible for sending or reviewing EPDS results in real-time. The study will be conducted until 214 high- and 214 low-risk patients have been randomized and followed through 6 months postpartum.
This study is a pilot project designed to generate preliminary data for a larger definitive trial. In the retrospective data, 10.1% of patients in the high-risk group and 2.0% of patients in the low-risk group had an EPDS score>12 at 6 weeks postpartum (non-responders were considered not to have a positive screen). Assuming the same rates in this prospective cohort, 107 individuals in each risk grouping would provide 80% power at alpha=0.05 to detect the same effect (one-sided Z-test). The study will enroll 107 individuals in the control arm in each risk grouping.
The study will employ an intent-to-treat approach, analyzing all randomized participants in their assigned groups, with a secondary per-protocol analysis limited to participants who completed their assigned screening protocol.
The primary endpoint, EPDS-positive screen (EPDS >12 vs ≤12), will be compared using chi-square tests within the standard screening group between the high- and low-risk groups. EPDS score at 2 weeks postpartum in the early screening group will be compared between high-risk and low-risk participants using Mann-Whitney U tests for median scores or t-tests for mean scores, if normally distributed. Secondary EPDS score endpoints at 6 weeks postpartum will be analyzed using the same methods. The binary endpoints of PPD incidence and mental health referral/treatment at 6 months (defined as the presence of a mood/depressive disorder diagnosis code, psychiatric medication prescription, or EPDS >12) will be compared between groups using chi-square tests. Feasibility endpoints, including EPDS completion rates at 2 and 6 weeks and positive screen rates (EPDS >10 and >12), will be analyzed using chi-square tests. Time to mental health referral or treatment initiation will be evaluated using Kaplan-Meier survival curves with log-rank tests for between-group comparisons. Model validation will be assessed through AUROC analysis for discrimination between those who develop PPD and those who do not, along with calibration plots comparing predicted versus observed PPD rates.
Using an intention-to-treat analytic plan, the primary analysis will compare rates of positive EPDS screening among the high- and low-risk groups in the control arm; non-responders to the EPDS screen will be considered "screen negative" to mirror the approach used for our sample size calculation. For other analyses, a complete-case approach will be used as the primary comparison method.
Regression will adjust for patient characteristics, such as race (White vs. non-White), language (English vs. non-English), age (\< vs ≥35 years), and mode of delivery (vaginal vs. cesarean delivery), to examine effect modification across various subgroups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Early PPD screening among individuals identified at high risk for PPD
Behavioral: Early PPD Screening
Routine care among individuals identified at high risk for PPD
arly PPD screening among individuals identified at low risk for PPD
Behavioral: Early PPD Screening
Routine care among individuals identified at low risk for PPD
Edinburgh Perinatal Depression Scale (EPDS) administered at approximately 2 weeks postpartum
Proportion of positive Edinburgh Postnatal Depression Scale (EPDS) screens at 6 weeks in the routine care group by postpartum depression (PPD) risk status
To compare rates of positive EPDS screens (EPDS \>12) at 6 weeks (in the routine care group) by PPD risk status (high vs. low)
Time frame: 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery
Edinburgh Peripartum Depression Scale (EPDS) scores at 2 weeks postpartum in the early screening group by PPD risk status
To compare EPDS scores at 2 weeks postpartum by PPD risk status (high vs. low) in the early screening group. EPDS score: range 0-30; higher scores are more strongly associated with PPD
Time frame: 2 weeks postpartum is defined as a period between 8-24 days after the day of delivery
Edinburgh Postnatal Depression Scale (EPDS) score at 6 weeks in the routine screening group by PPD risk status (high vs. low).
To compare EPDS scores at 6 weeks postpartum among women at high and low risk in the standard screening group. EPDS score: range 0-30; higher scores are more strongly associated with PPD
Time frame: 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery
Proportion of individuals with PPD at 6 months postpartum in the routine care group by PPD risk status
To compare the incidence of PPD (as defined by the presence of a diagnosis code for a mood or depressive disorder, a psychiatric medication prescription, or EPDS results \>12) at 6 months postpartum by PPD risk status (high vs. low) in the routine care group
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Proportion of individuals with PPD at 6 months postpartum in the early screening group by PPD risk status
To compare the incidence of PPD (as defined by the presence of a diagnosis code for a mood or depressive disorder, a psychiatric medication prescription, or EPDS results \>12) at 6 months postpartum by PPD risk status (high vs. low) in the early screening group
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Proportion of individuals with PPD (excluding EPDS diagnositic criteria) at 6 months postpartum in the routine care group by PPD risk status
To compare the incidence of PPD (as defined by the presence of a diagnosis code for a mood or depressive disorder, or a psychiatric medication prescription, but not an EPDS results \>12) at 6 months postpartum by PPD risk status (high vs. low) in the routine care group
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Proportion of individuals with PPD (excluding EPDS diagnostic criteria) at 6 months postpartum in the early screening group by PPD risk status
To compare the incidence of PPD (as defined by the presence of a diagnosis code for a mood or depressive disorder, or a psychiatric medication prescription, but not an EPDS results \>12) at 6 months postpartum by PPD risk status (high vs. low) in the early screening group
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Edinburgh Postnatal Depression Scale (EPDS) completion rates at 2 weeks postpartum in the early screening group by PPD risk status
To evaluate the feasibility of electronic-based EPDS screening at 2 weeks postpartum in the early screening group, as measured by screening completion rates
Time frame: 2 weeks postpartum is defined as a period between 8-24 days after the day of delivery
Edinburgh Postnatal Depression Scale (EPDS) completion rates at 6 weeks postpartum in the routine care group by PPD risk status
To examine EPDS completion rates at 6 weeks by PPD risk status (high vs. low) in the routine care group
Time frame: 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery
Proportion of positive Edinburgh Postnatal Depression Scale (EPDS) screens at 2 weeks in the early screening group by PPD risk status
To compare rates of positive EPDS screens (EPDS \>10 and \>12) at 2 weeks (early screening group) by PPD risk status (high vs. low)
Time frame: 2 weeks postpartum is defined as a period between 8-24 days after the day of delivery
Proportion of positive Edinburgh Postnatal Depression Scale (EPDS) screens at 6 weeks in the early screening group by PPD risk status
To compare rates of positive EPDS screens (EPDS \>10 and \>12) at 6 weeks postpartum (early screening group) by PPD risk status (high vs. low)
Time frame: 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery
Proportion of participants with mental health referrals (social work, therapy, psychology, psychiatry) and treatment (psychotherapy, medication prescription) within 6 months postpartum in the routine care group by PPD risk status
To compare mental health referrals and treatment within 6 months postpartum by PPD risk status (high vs. low) in the routine care group
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Proportion of participants with mental health referrals (social work, therapy, psychology, psychiatry) and treatment (psychotherapy, medication prescription) within 6 months postpartum in the early screening group by PPD risk status
To compare mental health referrals and treatment within 6 months postpartum by PPD risk status (high vs. low) in the early screening group
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Days between delivery and first diagnosis of a postpartum mood disorder within 6 months postpartum by PPD risk status
To compare days between delivery and first diagnosis of a postpartum mood disorder (based on diagnosis code and/or documentation with a clinical note) within 6 months postpartum by PPD risk status (high vs. low)
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Days between delivery and first mental health referral or treatment within 6 months postpartum in the routine care group by PPD risk status
To compare time to mental health referral and treatment within 6 months postpartum by PPD risk status (high vs. low) in the routine care group
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Days between delivery and first mental health referral or treatment within 6 months postpartum in the early screening group by PPD risk status
To compare time to mental health referral and treatment within 6 months postpartum by PPD risk status (high vs. low) in the early screening group
Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery
Change in Edinburgh Postnatal Depression Scale (EPDS) score between 2 and 6 weeks postpartum in the early screening group by PPD risk status
To compare the change in EPDS score between 2 and 6 weeks postpartum by PPD risk status (high vs. low) in the early screening group. EPDS score: range 0-30; higher scores are more strongly associated with PPD.
Time frame: 2 weeks postpartum is defined as a period between 8-24 days after the day of delivery; 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery
Plan to share: No
Started Nov 2026 (actual). Primary completion is estimated for Sep 2027, 10 months after the start.
Of 259 non-industry interventional studies with no phase under Depression, Postpartum, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 10 months is below that.
Counting every sponsor, half of 265 studies reached it within 23 months; a quarter within 11 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Sep 2026 → Nov 2026, primary completion Aug 2027 → Sep 2027 and completion Jan 2028 → Feb 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →